Skip to content

Perioperative Myocardial Protection of Esmolol in Patients with breast cancer Undergoing Neoadjuvant Chemotherapy:A single center, prospective randomized controlled study

Perioperative Myocardial Protection of Esmolol in Patients with breast cancer Undergoing Neoadjuvant Chemotherapy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072759
Enrollment
Unknown
Registered
2023-06-25
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Esmolol Treatment Group:Inject 0.3 mg/kg of esmolol intravenously 3 minutes before intubation, and continuously pump 50 ug/kg/min of esmolol during surgery until tracheal extubation
Control Group:Replacing Esmolol with Isophysiological Saline

Sponsors

Weihai Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: ? ASA grading I - II; ? BMI20~28kg/m2;? Patients who completed the anthracycline combined with paclitaxel regimen before surgery; ? Age 18-60 years old

Exclusion criteria

Exclusion criteria: ? Patients with bronchial asthma and severe chronic obstructive pulmonary disease; ? Long term use of analgesics and/or psychotropic drugs before surgery; ? Individuals who are allergic to anesthetic drugs; ? Those who cannot tolerate chemotherapy drugs; ? Patients with severe cardiovascular diseases (sinus bradycardia, first degree atrioventricular block, cardiogenic shock, heart failure); ? Severe liver and kidney function disorders; ? Pregnant or lactating women

Design outcomes

Primary

MeasureTime frame
hs-cTnT;CK-MB;LDH;NT-proBNP;

Secondary

MeasureTime frame
Left Heart Function Assessment;hemodynamics;Adverse cardiac reactions;

Countries

China

Contacts

Public ContactWang Xiaodong

Weihai Municipal Hospital

wxd1982819@126.com+86 135 0891 4062

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026